Genome Wide Study of Transcription in Yeast Redefines the Concept of Promoters
News Jan 29, 2009
Genes that contain instructions for making proteins make up less than 2% of the human genome. Yet, for unknown reasons, most of our genome is transcribed into RNA. The same is true for many other organisms that are easier to study than humans.
Researchers in the groups of Lars Steinmetz at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and Wolfgang Huber at the European Bioinformatics Institute (EMBL-EBI) in Hinxton, UK, have now unravelled how yeast generates its transcripts and have come a step closer to understanding their function.
The study, published online in Nature, redefines the concept of promoters (the start sites of transcription) contradicting the established notion that they support transcription in one direction only. The results are also representative of transcription in humans.
Investigating all transcripts produced in a yeast cell, the scientists found that most regions of the yeast genome produce several transcripts starting at the same promoter. These transcripts are interleaved and overlapping on the DNA. In contrast to what was previously thought, the vast majority of promoters seem to initiate transcription in both directions.
Not all of the produced transcripts are stable, many are degraded rapidly making it difficult to observe what they do. While some of the RNA molecules might be ‘transcriptional noise’ without function, other transcripts control the expression of genes and production of proteins.
The act of transcription itself is also likely to play an important role in regulation of gene expression. Transcribing one stretch of DNA might either help or in other cases interfere with the transcription of a gene close by. Moreover, transcripts without a current purpose can serve as ‘raw material for evolution’ and acquire new functions over time.
The results shed light on the complex organization of the yeast genome and the insights gained extend to transcription in humans. A better understanding of transcription mechanisms could find application in new technologies to tune gene regulation in the future.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.